Report : Europe Blood Plasma Derivatives Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type (Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, and Others), Application (Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, von Willebrand’s Diseases, and Others), and End User (Hospitals, Clinics, and Others)

At 9.1% CAGR, the Europe Blood Plasma Derivatives Market is speculated to be worth US$ 14,262.27 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe blood plasma derivatives market was valued at US$ 8,474.00 million in 2022 and is expected to reach US$ 14,262.27 million by 2028, registering a CAGR of 9.1% from 2022 to 2028. Increase in prevalence of blood disorders and rise in geriatric population are the critical factors attributed to the Europe blood plasma derivatives market expansion.

According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. As per the National Library of Medicine, in 2022, ~1% of all individuals (unselected population) have von Willebrand disease, i.e., 125 per 1 million. Research published in NLM in 2020 stated that 80 million people in European Union suffer from blood disorders, ranging from cancer to bleeding disorders. Hence, Plasma is a liquid portion of blood containing WBC and platelets. Blood plasma derivatives play a major role in stopping bleeding after an injury. Thus, the increasing prevalence of blood disorders across the world is one of the major driving factors promoting the growth of the blood plasma derivatives market growth.   

On the contrary, complicated reimbursement policies hurdles the growth of Europe blood plasma derivatives market.

The Europe blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held 45.5% market share in 2022, amassing US$ 3,835.61 million. It is projected to garner US$ 6637.51 million by 2028 to expand at 9.6% CAGR during 2022–2028.  

Based on application, the Europe blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held 34.7% market share in 2022, amassing US$ 2,920.06 million. It is projected to garner US$ 5,089.37 million by 2028 to expand at 9.7% CAGR during 2022–2028.

The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held 59.7% market share in 2022, amassing US$ 5,068.85 million. It is projected to garner US$ 8,451.22 million by 2028 to expand at 8.9% CAGR during 2022–2028.  

Based on country, the Europe blood plasma derivatives market is segmented into Germany, France, UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 27.1% market share in 2022. It was assessed at US$ 2,295.49 million in 2022 and is likely to hit US$ 3,914.99 million by 2028, exhibiting a CAGR of 9.3% during the forecast period.  

Key players dominating the Europe blood plasma derivatives market are Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; Takeda Pharmaceutical Co Ltd; CSL Behring LLC; LFB SA; Kedrion SpA; and Fusion Health Care Pvt Ltd, among others.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com

Download Free PDF Brochure